(NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adults and adolescents aged 12 years and older with ...

The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.

With a market cap of $62.4 billion, Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

A new study in England shows a strong link between higher rates of chest x-ray referrals in general practice patients with symptoms, such as persistent cough, and earlier lung cancer diagnoses, along ...

In an analysis of Medicare's top-selling brand-name oncology drugs, researchers found that while the vast majority provided high added therapeutic benefit, 10 were classified as providing low or no ...

The vast majority of Medicare's top-selling brand-name oncology drugs in 2022 provided high added therapeutic benefit. Ten drugs were classified as low or no added therapeutic benefit compared ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945’s potential as a monotherapy or in combination with the second-line immunotherapy Libtayo. The company ...

and cemiplimab (Libtayo), an anti–PD-1 agent, in patients with advanced melanoma. 1 The first-in-human, phase 1, open-label, dose-escalation and cohort expansion trial sought to evaluate the safety ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo. The company ...